| 1 |
Three-dimensional chromatin landscapes in T cell acute lymphoblastic leukemia
Andreas Kloetgen et al. · Nature Genetics
Open access |
23 Mar 2020 |
238 |
| 2 |
Evaluating the state of the science for adeno-associated virus integration: An integrated perspective
Denise E. Sabatino, Frederic D. Bushman, Randy J. Chandler et al. · Molecular Therapy
Open access |
10 Jun 2022 |
214 |
| 3 |
Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy
Daniel Philip Judge et al. · Journal of the American College of Cardiology
Open access |
Mar 2025 |
57 |
| 4 |
Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C
Anna E. Maciag et al. · Cancer Discovery
Open access |
6 Dec 2024 |
55 |
| 5 |
Efficacy and Safety of Encaleret in Autosomal Dominant Hypocalcemia Type 1
Rachel Ilana Gafni, Iris Ruth Hartley, Kelly Lauter Roszko et al. · New England Journal of Medicine
Open access |
27 Sep 2023 |
48 |
| 6 |
Early Increase in Serum Transthyretin by Acoramidis Independently Predicts Improved Survival in TTR Amyloid Cardiomyopathy
Mathew S. Maurer et al. · Journal of the American College of Cardiology
Open access |
May 2025 |
45 |
| 7 |
Modulating fast skeletal muscle contraction protects skeletal muscle in animal models of Duchenne muscular dystrophy
Alan J. Russell et al. · Journal of Clinical Investigation
Open access |
30 Mar 2023 |
38 |
| 8 |
Patient and family experience with transthyretin amyloid cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN) amyloidosis: results of two focus groups
David J. Rintell, Dena Heath, Florencia Braga Mendendez et al. · Orphanet Journal of Rare Diseases
Open access |
8 Feb 2021 |
38 |
| 9 |
Multi-ancestry GWAS meta-analyses of lung cancer reveal susceptibility loci and elucidate smoking-independent genetic risk
Bryan R. Gorman et al. · Nature Communications
Open access |
4 Oct 2024 |
33 |
| 10 |
BBO-10203 inhibits tumor growth without inducing hyperglycemia by blocking RAS-PI3Kα interaction
Dhirendra K. Simanshu et al. · Science
|
12 Jun 2025 |
30 |
| 11 |
Optimized AAV Vectors for TMC1 Gene Therapy in a Humanized Mouse Model of DFNB7/11
Irina Marcovich, Nicholas K. Baer, Olga Shubina-Oleinik et al. · Biomolecules
Open access |
29 Jun 2022 |
30 |
| 12 |
Thrombotic Microangiopathy Associated with Systemic Adeno-Associated Virus Gene Transfer: Review of Reported Cases
Genevieve A. Laforet · Human Gene Therapy
|
16 Jan 2025 |
27 |
| 13 |
Gene-based therapeutics for rare genetic neurodevelopmental psychiatric disorders
Beverly L. Davidson, Guangping Gao, Elizabeth Berry‐Kravis et al. · Molecular Therapy
Open access |
17 May 2022 |
27 |
| 14 |
Study design challenges and strategies in clinical trials for rare diseases: Lessons learned from pantothenate kinase-associated neurodegeneration
Aleksandar Videnović, Helle Cecilie Viekilde Pfeiffer, Anna Tylki‐Szymańska et al. · Frontiers in Neurology
Open access |
8 Mar 2023 |
26 |
| 15 |
Revealing the mechanism of action of a first-in-class covalent inhibitor of KRASG12C (ON) and other functional properties of oncogenic KRAS by 31P NMR
Alok Kumar Sharma, Jun Pei, Yue Cheng Yang et al. · Journal of Biological Chemistry
Open access |
16 Jan 2024 |
22 |
| 16 |
Enrichment of adeno‐associated virus serotype 5 full capsids by anion exchange chromatography with dual salt elution gradients
R. Ashton Lavoie, Jeffrey T. Zugates, Andrew T. Cheeseman et al. · Biotechnology and Bioengineering
Open access |
31 May 2023 |
22 |
| 17 |
Biophysical and structural analysis of KRAS switch-II pocket inhibitors reveals allele-specific binding constraints
Patrick Alexander, Albert H. Chan, Dana Rabara et al. · Journal of Biological Chemistry
Open access |
3 Jun 2025 |
17 |
| 18 |
Effects of soluble guanylate cyclase stimulator on renal function in ZSF-1 model of diabetic nephropathy
Lufei Hu, Yinhong Chen, Xiaoyan Zhou et al. · PLoS ONE
Open access |
27 Jan 2022 |
15 |
| 19 |
Removal of host cell proteins from cell culture fluids by weak partitioning chromatography using peptide-based adsorbents
R. Ashton Lavoie, Wenning Chu, Joseph H. Lavoie et al. · Separation and Purification Technology
|
14 Oct 2020 |
15 |
| 20 |
Challenges and strategies for clinical trials in propionic and methylmalonic acidemias
Jerry E. Vockley, Barbara K. Burton, Agnieszka Jurecka et al. · Molecular Genetics and Metabolism
Open access |
21 May 2023 |
13 |
| 21 |
OncoVEXmGM-CSFexpands tumor antigen-specific CD8+ T-cell response in preclinical models
Juan Camilo Estrada, Jinghui Zhan, Petia Mitchell et al. · Journal for ImmunoTherapy of Cancer
Open access |
May 2023 |
13 |
| 22 |
A light-gated transcriptional recorder for detecting cell-cell contacts
Kelvin F Cho, Shawn M Gillespie, Nicholas A Kalogriopoulos et al. · eLife
Open access |
28 Feb 2022 |
13 |
| 23 |
Effect of Acoramidis on Recurrent and Cumulative Cardiovascular Outcomes in ATTR-CM
Ahmad Masri et al. · Journal of the American College of Cardiology
Open access |
28 Sep 2025 |
12 |
| 24 |
Families’ Experience of Pediatric Onset Multiple Sclerosis
Theodore P. Cross, Alane K. Shanks, Lisa V. Duffy et al. · Journal of Child & Adolescent Trauma
Open access |
8 Jan 2019 |
12 |
| 25 |
Planning for progress: A US regulatory approach to advancing the clinical development of gene therapies
Mantej Chhina, Daniela Drago, Adora Ndu · Molecular Therapy
Open access |
17 May 2022 |
11 |
| 26 |
Acoramidis produces near-complete TTR stabilization in blood samples from patients with variant transthyretin amyloidosis that is greater than that achieved with tafamidis
Alan X. Ji, P. Wong, Daniel Philip Judge et al. · European Heart Journal
Open access |
Nov 2023 |
10 |
| 27 |
Efficacy of Acoramidis in Wild-Type and Variant Transthyretin Amyloid Cardiomyopathy
Kevin Michael Alexander et al. · JAMA Cardiology
Open access |
8 Nov 2025 |
8 |
| 28 |
Differential Binding Affinities and Kinetics of Transthyretin Stabilizers
Alan X. Ji, Andreas Betz, Uma Sinha · Journal of Cardiovascular Pharmacology
Open access |
5 Jun 2025 |
8 |
| 29 |
Acoramidis for Transthyretin Amyloid Cardiomyopathy: Open-Label Extension Study Long-Term Follow-Up
Ahmad Masri, Mandar A. Aras, Martha Grogan et al. · Journal of Cardiac Failure
Open access |
9 Apr 2025 |
8 |
| 30 |
Circulating transthyretin and retinol binding protein 4 levels among middle-age V122I TTR carriers in the general population
NICHOLAS S. HENDREN, James A. de Lemos, Jarett D. Berry et al. · Amyloid
Open access |
6 Mar 2024 |
8 |
| 31 |
A Multi-Laboratory, Multi-Platform Analysis of the Multi-Attribute Method
J. J. Shipman, Mercy A. Oyugi, Tim Andres Marzan et al. · Pharmaceuticals
Open access |
25 Oct 2025 |
6 |
| 32 |
Multi-ancestry genome-wide association meta-analysis of mosaic loss of chromosome Y in the Million Veteran Program identifies 240 novel loci
Michael Francis et al. · medRxiv
PreprintOpen access |
25 Apr 2024 |
6 |
| 33 |
Sonoporation‐Enhanced Delivery of STING Agonist Induced Robust Immune Modulation and Tumor Regression
Jun Xu, Nicolas Solban, Yun Wang et al. · Advanced Therapeutics
Open access |
24 Aug 2021 |
6 |
| 34 |
Structure, motion, and multiscale search of traveling networks
Nate Cira, Morgan L Paull, Shayandev Sinha et al. · Nature Communications
Open access |
26 Feb 2025 |
5 |
| 35 |
A calcium-sensing receptor allelic series and underdiagnosis of genetically driven hypocalcemia
Jeremy B. Chang et al. · The American Journal of Human Genetics
Open access |
15 Jul 2025 |
4 |
| 36 |
Increase in serum TTR levels observed with acoramidis treatment in patients with transthyretin amyloid cardiomyopathy (ATTR-CM): insights from ATTRibute-CM and its open-label extension
Matthew J. Maurer, Francesco Cappelli, M Fontana et al. · European Heart Journal
Open access |
Oct 2024 |
4 |
| 37 |
Validation of a novel western blot assay to monitor patterns and levels of alpha dystroglycan in skeletal muscle of patients with limb girdle muscular dystrophies
Thulashitha Rajasingham, Hector M. Rodriguez, Andreas Betz et al. · Journal of Muscle Research and Cell Motility
Open access |
18 Apr 2024 |
4 |
| 38 |
Evolution of patient characteristics and outcomes in ATTR-CM clinical trials: A systematic review
Ahmad Masri, R. Scott Wright, Marissa Blieden Betts et al. · Progress in Cardiovascular Diseases
ReviewOpen access |
16 Apr 2026 |
3 |
| 39 |
Long-Term Durability of Acoramidis Efficacy in Transthyretin Amyloid Cardiomyopathy
Prem Soman et al. · JAMA Cardiology
Open access |
30 Mar 2026 |
3 |
| 40 |
Infigratinib low dose therapy is an effective strategy to treat hypochondroplasia
Benoît Demuynck, Bhavik P. Shah, Franck Mayeux et al. · Journal of Bone and Mineral Research
Open access |
24 Jun 2025 |
3 |
| 41 |
IN PARTICIPANTS TREATED WITH ACORAMIDIS, ADDITION OF CONCOMITANT TAFAMIDIS DID NOT FURTHER INCREASE SERUM TTR LEVELS
Mathew S. Maurer, Francesco Cappelli, Marianna Fontana et al. · Journal of the American College of Cardiology
Open access |
29 Mar 2025 |
3 |
| 42 |
Urine N -Acetylaspartate Distinguishes Phenotypes in Canavan Disease
Amanda M. Nagy, Florian Eichler, Annette E. Bley et al. · Human Gene Therapy
Open access |
4 Dec 2024 |
3 |
| 43 |
Informative g-Priors for Mixed Models
Yu-Fang Chien, Haiming Zhou, Timothy Hanson et al. · Stats
Open access |
16 Jan 2023 |
3 |
| 44 |
Acoramidis, Serum Transthyretin, and Cardiovascular Outcomes in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Trial
Amrut V. Ambardekar et al. · Journal of Cardiac Failure
Open access |
May 2026 |
2 |
| 45 |
A first-in-human phase 1 study of the SHP2 inhibitor BBP-398 in patients with advanced solid tumors
Gerald Steven Falchook, Camila Bragança Xavier, David van Veenhuyzen et al. · npj Precision Oncology
Open access |
28 Feb 2026 |
2 |
| 46 |
Limb-Girdle Muscular Dystrophy Scientific Workshop
Matthew Wicklund, Lindsay N. Alfano, Nicholas Elwood Johnson et al. · Neurology Clinical Practice
|
30 Jul 2025 |
2 |
| 47 |
Patient Experience Data (PED) in 2019–2023 US FDA NME Drug Approvals: Analysis and Recommendations
Jewell D. Martin, Darcy Frear, Samantha A. Roberts et al. · Therapeutic Innovation & Regulatory Science
|
9 May 2025 |
2 |
| 48 |
PRIMARY ENDPOINT EFFICACY RESULTS IN THE ATTRIBUTE-CM STUDY: PRE-SPECIFIED SENSITIVITY ANALYSES ADDRESSED TAFAMIDIS USE
Daniel Philip Judge, Laura Piera Obici, Sumeet Singh Mitter et al. · Journal of the American College of Cardiology
Open access |
29 Mar 2025 |
2 |
| 49 |
Infigratinib Versus Placebo for Patients with High-risk Resected Urothelial Cancer Bearing an FGFR3 Genomic Alteration: Results from the PROOF302 Phase 3 Trial
Sumanta Kumar Pal et al. · European Urology
|
4 Apr 2024 |
2 |
| 50 |
The need for ethical and pragmatic strategies for sample and data collection during public health emergencies—minimizing missed opportunities
Rafael D. Escandon, Bettina Heidecker · European Heart Journal
|
9 Feb 2021 |
2 |